Praxis Precision Medicines remains a Hold as valuation now reflects high expectations for ulixacaltamide and its epilepsy ...

BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

BOSTON - Praxis Precision Medicines Inc. (NASDAQ: PRAX) announced that the Independent Data Monitoring Committee (IDMC) has recommended halting Study 1 of the Essential3 program, which is evaluating ...

The latest announcement is out from Praxis Precision Medicines ( ($PRAX) ). On December 29, 2025, Praxis Precision Medicines, Inc. reported that ...

BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

Tuesday, Praxis Precision Medicines Inc . (NASDAQ:PRAX) shares received a boost as Truist Securities increased its price target for the company to $175 from $150, while maintaining a Buy rating. The ...

I maintain a Hold rating on Praxis Precision Medicines, Inc., driven by positive open-label Radiant data for vormatrigine in epilepsy but tempered by clinical risks. Vormatrigine achieved a 56.3% ...

On Friday, Praxis Precision Medicines, Inc. (NASDAQ:PRAX) released interim data from Study 1 of the Essential3 program of ulixacaltamide in essential tremor (ET). The Independent Data Monitoring ...

Praxis Precision Medicines has scored another midphase win in epilepsy this year, with its sodium channel inhibitor shown to reduce seizures in children with two specific types of the neurological ...

Praxis Precision Medicines is converting its EMBRAVE3 study of elsunersen for children suffering from a developmental disease into a single-arm study after meeting with the Food and Drug ...